EUVIMEDEUVIMED entdecken
Open Access

Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls

Tali Eviatar iD, Adi Pappo, Tal Freund, Yishai Friedlander, Ori Elkayam, David Hagin, Merav Heshin-Bekenstein iD

Clinical and Experimental Immunology · 2024

DOI: 10.1093/cei/uxae044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2024. Verfasst von Tali Eviatar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19, SARS-CoV-2, Rheumatic Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This paper aims to compare the cellular immune response to the SARS-CoV-2 BNT162b2 vaccine of pediatric patients with autoimmune inflammatory rheumatic disease (pAIIRD) and healthy controls. A prospective longitudinal study was conducted between April 2021 and December 2022 at the Tel Aviv Medical Center. Children <18 years, with pediatric-onset AIIRD and healthy controls, who have received at least two doses of the BNT162b2 vaccine, were included. Humoral response was evaluated by serum levels of anti-SARS-CoV-2 receptor-binding domain antibodies. Cellular response was evaluated by flow cytometry, measuring IFNγ and TNFα production by CD4+ T cells following stimulation with SARS-CoV-2 Spike peptide mix. The study included 20 pAIIRD patients and 11 controls. The mean age of participants was 12.6 ± 2.94 years, with 58.1% females. The cellular response to the BNT162b2 vaccine was statistically similar in both groups. However, the humoral response was statistically lower in pAIIRD compared with the healthy control group. There was no statistically significant correlation between the humoral response and cellular response. During the study period, 43.75% of AIIRD children and 72.7% of controls had a breakthrough COVID-19 infection (P = 0.48). Bivariate models examining the effect of the cellular response and presence of an AIIRD on breakthrough infections found no effect. Compared with healthy controls, pAIIRD demonstrated similar cellular responses. Patients showed reduced humoral response compared with healthy adolescents, but similar breakthrough infection rates. These findings may support the importance of the cellular response in protecting against COVID-19 infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BNT162 VaccineCOVID-19SARS-CoV-2Rheumatic DiseasesImmunity, CellularAntibodies, ViralHumansFemaleMaleChildAdolescentProspective StudiesAutoimmune DiseasesLongitudinal StudiesCOVID-19 VaccinesSpike Glycoprotein, CoronavirusImmunity, HumoralCD4-Positive T-LymphocytesInterferon-gamma

Stichwörter der Autor:innen

BNT162b2 vaccineCOVID-19cellular immunityhumoral immunityjuvenile arthritisrheumatic diseases

Substanzen

BNT162 VaccineAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, CoronavirusInterferon-gamma

Autor:innen und Institutionen

  • Rheumatology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Pediatric Rheumatology Unit, Schneider Children's Hospital, Petach Tikva, Israel.
  • Department of Allergy and Clinical Immunology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • StatistiX, Beer Tuvya, Israel.
  • Pediatric Rheumatology Service, Dana Children's Hospital of Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

ORCID-Profile: Tali Eviatar, Merav Heshin-Bekenstein

Zitieren

APA

Eviatar, T., Pappo, A., Freund, T., Friedlander, Y., Elkayam, O., Hagin, D., & Heshin-Bekenstein, M. (2024). Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae044

Vancouver

Eviatar T, Pappo A, Freund T, Friedlander Y, Elkayam O, Hagin D, et al. Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls. Clinical and Experimental Immunology. 2024. doi:10.1093/cei/uxae044

BibTeX
@article{Eviatar2024,
  author = {Eviatar, Tali and Pappo, Adi and Freund, Tal and Friedlander, Yishai and Elkayam, Ori and Hagin, David and Heshin-Bekenstein, Merav},
  title = {Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls},
  journal = {Clinical and Experimental Immunology},
  year = {2024},
  doi = {10.1093/cei/uxae044}
}
Kostenlos starten →